AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
This Quarter Return
+46.42%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$502M
AUM Growth
+$502M
(+64%)
Cap. Flow
+$75.9M
Cap. Flow
% of AUM
15.13%
Top 10 Holdings %
Top 10 Hldgs %
46.98%
Holding
91
New
13
Increased
21
Reduced
21
Closed
11
Top Buys
| 1 |
IMGN
Immunogen Inc
IMGN
|
$41.6M |
| 2 |
LIAN
LianBio American Depositary Shares
LIAN
|
$13.9M |
| 3 |
Celldex Therapeutics
CLDX
|
$9.92M |
| 4 |
Nuvalent
NUVL
|
$9.2M |
| 5 |
Xenon Pharmaceuticals
XENE
|
$7.35M |
Top Sells
| 1 |
Apogee Therapeutics
APGE
|
$14.2M |
| 2 |
Kura Oncology
KURA
|
$9.56M |
| 3 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$6.57M |
| 4 |
Cytokinetics
CYTK
|
$5.87M |
| 5 |
Mersana Therapeutics
MRSN
|
$4.29M |
Sector Composition
| 1 | Healthcare | 94.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Viking Therapeutics
VKTX
$3.02B
| $5.58M | 1.02% |
300,000
| – | – |
|
27
Savara
SVRA
$591M
| $5.41M | 0.99% |
1,150,000
| – | – |
|
|
CMPS
28
Compass Pathways
CMPS
$452M
| $4.81M | 0.88% |
+550,000
| New | +$4.81M |
|
29
Apellis Pharmaceuticals
APLS
$3.51B
| $4.49M | 0.82% |
75,000
+35,000
| +88% | +$2.1M |
|
30
MoonLake Immunotherapeutics
MLTX
$3.78B
| $4.29M | 0.78% |
70,988
+20,988
| +42% | +$1.27M |
|
31
Dynavax Technologies
DVAX
$1.19B
| $4.19M | 0.77% |
300,000
+100,000
| +50% | +$1.4M |
|
32
AstraZeneca
AZN
$255B
| $4.04M | 0.74% |
60,000
| – | – |
|
33
Axsome Therapeutics
AXSM
$6.09B
| $3.98M | 0.73% |
+50,000
| New | +$3.98M |
|
|
SWTX
34
DELISTED
SpringWorks Therapeutics
SWTX
| $3.65M | 0.67% |
100,000
+58,419
| +140% | +$2.13M |
|
35
Relay Therapeutics
RLAY
$709M
| $3.3M | 0.6% |
+300,000
| New | +$3.3M |
|
36
BridgeBio Pharma
BBIO
$9.91B
| $3.23M | 0.59% |
80,000
+50,000
| +167% | +$2.02M |
|
37
Krystal Biotech
KRYS
$4.35B
| $3.1M | 0.57% |
25,000
-32,500
| -57% | -$4.03M |
|
38
Cullinan Oncology
CGEM
$456M
| $3.06M | 0.56% |
+300,000
| New | +$3.06M |
|
39
Tango Therapeutics
TNGX
$745M
| $2.97M | 0.54% |
300,274
-49,726
| -14% | -$492K |
|
40
argenx
ARGX
$44.2B
| $2.85M | 0.52% |
+7,500
| New | +$2.85M |
|
|
41
Kura Oncology
KURA
$732M
| $2.75M | 0.5% |
191,535
-665,000
| -78% | -$9.56M |
|
42
EyePoint Pharmaceuticals
EYPT
$827M
| $2.54M | 0.46% |
+109,900
| New | +$2.54M |
|
43
Ascendis Pharma
ASND
$12.1B
| $2.52M | 0.46% |
20,000
-26,400
| -57% | -$3.33M |
|
|
44
Mersana Therapeutics
MRSN
$34.8M
| $2.32M | 0.42% |
40,000
-74,000
| -65% | -$4.29M |
|
45
Immatics
IMTX
$662M
| $2.11M | 0.38% |
200,000
| – | – |
|
46
Penumbra
PEN
$10.5B
| $1.89M | 0.34% |
+7,500
| New | +$1.89M |
|
47
Tourmaline Bio
TRML
$645M
| $1.78M | 0.33% |
68,081
+28,081
| +70% | +$735K |
|
48
ADC Therapeutics
ADCT
$370M
| $1.68M | 0.31% |
1,013,540
-86,460
| -8% | -$144K |
|
49
Vaxcyte
PCVX
$4.17B
| $1.57M | 0.29% |
25,000
| – | – |
|
50
KalVista Pharmaceuticals
KALV
$713M
| $1.54M | 0.28% |
125,969
-152,323
| -55% | -$1.87M |
|